Clay Siegall is a biomedicine and genetics expert who has worked as a researcher in various pharmaceutical corporations across the United States. He has made significant accomplishments and is a co-founder of Seattle Genetics Company. The firm has also hired him as the chairperson and president. The organization has currently made important steps in the development of cancer treatments that are sold across the world from the time that it was founded in 1998. Clay has been in the industry for several years, and this has enabled him to gain excellent skills. He has been working with the scientists of the firm in developing excellent cures that can be used in curing different cancers. Siegall is a good administrator, and his management skills have enabled the company to be successful. The firm currently sells various antibody drugs that have healed many patients across the globe.
Clay has been working tirelessly to make sure that the company is allowed to be part of technologies such as AbbVie, Roche, GlaxoSmithKline, and Pfizer. He was appointed by Ultragenyx in 2014 to serve on its board. Dr. Siegall had an opportunity to work for various organizations before he was involved in the formation of Seattle Genetics Company. He was hired by the Bristol-Myers Squibb Pharmaceutical Research Institute in 1991, and he served it until 1997. The science expert also served bodies such as National Cancer Institute and National Cancer Institute from 1988 to mid-1991. He has also served on the management board of top biotechnological corporations such as Mirna Therapeutics and BioPharmaceuticals. He is an alumnus of the University of Maryland where he was awarded a zoology degree. Clay then enrolled at the George Washington University and graduated from the institution with a Ph.D. in Genetics.
In 2013, Dr. Siegall was appointed by Mirna Therapeutics to serve it as its external board member. He has played a major part in assisting the firm to develop micro-RNA-based therapeutics that are used in bettering cancer research. His experience is highly treasured by the company. Clay has dedicated his profession to conducting extensive research to discover ideal drugs for treating cancer patients.